Paul Sargeant

Paul Sargeant is the President and CEO of Circular Genomics, a San Diego biotech building blood tests around circular RNA - the loop-shaped, unusually stable molecules most of the field once ignored. A Cambridge-trained physiologist with 25 years across Fortune 100 firms and venture-backed startups in the US, Europe and Asia, he took the helm in 2023, shepherded the launch of the MindLight test predicting which depression patients will respond to SSRIs, moved headquarters into Lilly Gateway Labs, and closed a $15M Series A in December 2025 to push the same platform toward early Alzheimer's detection.